Gartner Survey: Industry Demands Better Guidance from FDA on CFR-11 Compliance | GenomeWeb

A recent survey of the biopharmaceutical industry conducted by GartnerG2 indicates that the FDA could do a much better job of communicating the specific steps necessary to become compliant with the 21 CFR Part 11 regulation for electronic records submitted as part of drug applications.

The survey’s preliminary findings “reinforce the need for clear guidance from the FDA,” Gartner healthcare analyst Jonathan Edwards told BioInform. “There’s a lot of confusion about the regulation.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.